Skip to main content
main-content

01.12.2015 | Research article | Ausgabe 1/2015 Open Access

BMC Urology 1/2015

Degarelix therapy for prostate cancer in a real-world setting: experience from the German IQUO (Association for Uro-Oncological Quality Assurance) Firmagon® registry

Zeitschrift:
BMC Urology > Ausgabe 1/2015
Autoren:
Götz Geiges, Thomas Harms, Gerald Rodemer, Ralf Eckert, Frank König, Rolf Eichenauer, Jörg Schroder
Wichtige Hinweise

Competing interests

G. Geiges: None.
T. Harms: None.
G. Rodemer: None.
R. Eckert: None.
F. König: Advisory board Bayer, Lilly, Sanofi, Ferring, Berlin-Chemie.
R. Eichenauer: board member/consultant and received travel support/honoraria for lectures from: Astellas, AstraZeneca, Bayer Health Care, Ferring, Ipsen, Janssen-Cilag, Medacs, Novartis, Pfizer, Sanofi-Aventis, Takeda and Teva.
J. Schroder: honoraria as advisory board meeting participant for Ferring.

Authors’ contributions

All authors were involved in the conception and design of the study; all authors made substantial contributions to the acquisition of data; all authors were involved in revising the manuscript critically for important intellectual content. All authors read and approved the final manuscript.

Abstract

Background

We investigated the use of the gonadotropin-releasing hormone (GnRH) antagonist degarelix in everyday clinical practice using registry data from uro-oncology practices in Germany.

Methods

Data were analysed retrospectively from the IQUO (Association for uro-oncological quality assurance) patient registry. Data were prospectively collected from all consecutive PCa patients treated with degarelix (n = 1010) in 138 uro-oncology practices in Germany between May 2009 and December 2013.

Results

Median overall survival had not yet been reached in the all-patient group or in subgroups who had or had not received prior hormonal therapy (HT). Cox regression analysis showed that patients who had received prior HT (n = 542) had a 58 % increased mortality risk (hazard ratio 1.58, 95 % CI 1.20–2.09) versus patients who had not (n = 468) (p = 0.001). Also, in patients who had received prior luteinizing hormone-releasing hormone (LHRH) analogue therapy (LHRH agonists or GnRH antagonists), median time to PSA progression was shorter (209 weeks) than in those who had not received prior LHRH analogues (n = 555; median PSA progression-free survival not yet reached). Degarelix was generally well tolerated.

Conclusions

Degarelix was effective and well tolerated in everyday clinical practice, confirming observations from clinical studies. Patients who received prior HT appeared to have a significantly higher mortality risk.
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2015

BMC Urology 1/2015 Zur Ausgabe

Neu im Fachgebiet Urologie

Meistgelesene Bücher in der Urologie

2016 | Buch

Anogenitale Hautkrankheiten

Erkennen, Befunden, Behandeln

Hautkrankheiten im Bereich Genitale werden werden oft erstmals von einem Facharzt beobachtet, der sich mit anderen genitalen Beschwerden beschäftigt – der Urologe bei Männern oder der Gynäkologe bei Frauen. Dieses Buch schult den Blick für anogenitale Dermatosen und gibt Tipps zur Therapie.

Herausgeber:
Walter Krause, Isaak Effendy

2015 | Buch

Inkontinenz- und Deszensuschirurgie der Frau

Harninkontinenz ist eines der häufigsten Symptome in der Urologie und Gynäkologie. OP-Atlas, unverzichtbarer Ratgeber, kompaktes Nachschlagewerk in einem: Mithilfe dieses Buches werden Sie Spezialist in Sachen Inkontinenz- und Deszensuschirurgie.

Herausgeber:
Rainer Hofmann, Uwe Wagner

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Urologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise